ReViral and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Sisunatovir in China Mar 2, 2021 by ReViral Ltd Read More
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection Aug 4, 2020 by ReViral Ltd Read More
Impact of RSV highlighted on BBC Radio 4’s ‘Inside Health’ Programme Feb 4, 2020 by ReViral Ltd Read More
ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and Chemotherapy Jan 27, 2020 by ReViral Ltd Read More
